Attenuation of replication-competent adenovirus serotype 26 vaccines by vectorization

Clinical and Vaccine Immunology

Volumn 22, Issue 11, 2015, Pages 1166-1175

  Maxfield, Lori F ^a   Abbink, Peter ^a   Stephenson, Kathryn E ^a   Borducchi, Erica N ^a   Ng'Ang'A, David ^a   Kirilova, Marinela M ^a   Paulino, Noelix ^a   Boyd, Michael ^a   Shabram, Paul ^b   Ruan, Qian ^b   Patel, Mayank ^b   Baroucha, Dan H ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b PaxVax   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DRUG CARRIER; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID VECTOR; ADENOVIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ADENOVIRIDAE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENVELOPE GENE; GENE DELETION; GENE INSERTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICATION COMPETENT ADENOVIRUS SEROTYPE 26; SEROTYPE; TRANSGENE; VACCINE PRODUCTION; VIRUS ATTENUATION; VIRUS INFECTIVITY; VIRUS REPLICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSIOLOGY;

ADENOVIRUS VACCINES; ADENOVIRUSES, HUMAN; CLINICAL TRIALS, PHASE I AS TOPIC; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MUTAGENESIS, INSERTIONAL; SEROGROUP; VIRUS REPLICATION;

EID: 84945581684     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00510-15     Document Type: Article

References (42)

1. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93. http://dx.doi.org/10.1038/nature10766.
2. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL. 2013. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155: 531-539. http://dx.doi.org/10.1016/j.cell.2013.09.061.
3. Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA, Jr, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijtens M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH. 2015. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211: 518-528. http://dx.doi.org/10.1093/infdis/jiu485.
4. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. 2013. First-inhuman evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207: 240-247. http://dx.doi.org/10.1093/infdis/jis670.
5. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR. 2013. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 207: 248-256. http://dx.doi.org/10.1093/infdis/jis671.
6. Parks CL, Picker LJ, King CR. 2013. Development of replicationcompetent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 8: 402-411. http://dx.doi.org/10.1097/COH.0b013e328363d389.
7. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16: 319-323. http://dx.doi.org/10.1038/nm.2089.
8. Thurmond J, Yoon H, Kuiken C, Yusim K, Perkins S, Theiler J, Bhattacharya T, Korber B, Fischer W. 2008. Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24: 1639-1640. http://dx.doi.org/10.1093/bioinformatics/btn251.
9. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106. http://dx.doi.org/10.1038/nm1461.
10. Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG, Szinger JJ, Korber B, Barouch DH. 2012. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-regiononly HIV-1 immunogens in rhesus monkeys. J Virol 86: 11434-11440. http://dx.doi.org/10.1128/JVI.01779-12.
11. + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 16: 324-328. http://dx.doi.org/10.1038/nm.2108.
12. Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P. 2012. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced Tcell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One 7: E43396. http://dx.doi.org/10.1371/journal.pone.0043396.
13. Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, Avanzini JB, Guenther B, Garduno F, Jow L, Snarsky V, Ishioka G, Dong X, Vang L, Newman MJ, Mayall T. 2012. Pre-clinical evaluation of a replicationcompetent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One 7: E31177. http://dx.doi.org/10.1371/journal.pone.0031177.
14. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. 2013. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 13: 238-250. http://dx.doi.org/10.1016/S1473-3099(12)70345-6.
15. Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, Smith J, Gurwith M, Golding H. 2015. Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization. PLoS One 10: E0115476. http://dx.doi.org/10.1371/journal.pone .0115476.
16. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663. http://dx.doi.org/10.1128/JVI.02696-06.
17. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271. http://dx.doi.org/10.1128/JVI.77.15.8263-8271.2003.
18. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172: 6290-6297. http://dx.doi.org/10.4049/jimmunol.172.10 .6290.
19. + T-lymphocyte epitope immunodominance hierarchies. J Virol 80: 11991-11997. http://dx.doi.org/10 .1128/JVI.01348-06.
20. Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG. 2006. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24: 6893-6904. http://dx.doi.org/10.1016/j.vaccine.2006.06.009.
21. Abbink P, Maxfield LF, Ng'ang'a D, Borducchi EN, Iampietro MJ, Bricault CA, Teigler JE, Blackmore S, Parenteau L, Wagh K, Handley SA, Zhao G, Virgin HW, Korber B, Barouch DH. 2015. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J Virol 89: 1512-1522. http://dx.doi.org/10.1128/JVI.02950-14.
22. Thomas MA, Song R, Demberg T, Vargas-Inchaustegui DA, Venzon D, Robert-Guroff M. 2013. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. PLoS One 8: E76344. http://dx.doi.org/10.1371/journal.pone.0076344.
23. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW. 2010. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957. http://dx.doi.org/10.1016/j.vaccine.2009.10.145.
24. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francis-chetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409. http://dx.doi.org/10.1016/j.cell.2008.01.016.
25. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH. 2008. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 82: 4844-4852. http://dx.doi.org/10.1128/JVI .02616-07.
26. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91. http://dx.doi.org/10.1038/nature07469.
27. Loré K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, Koup RA. 2007. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179: 1721-1729. http://dx.doi.org/10.4049/jimmunol.179.3.1721.
28. Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, Barouch DH. 2012. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 86: 10862-10865. http://dx.doi.org/10 .1128/JVI.00928-12.
29. Teigler JE, Iampietro MJ, Barouch DH. 2012. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol 86: 9590-9598. http://dx.doi.org/10.1128/JVI.00740-12.
30. Mandell G, Bennett J, Dolin R. 2010. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. Churchill Livingstone/Elsevier, Philadelphia, PA.
31. Joag SV, Liu ZQ, Stephens EB, Smith MS, Kumar A, Li Z, Wang C, Sheffer D, Jia F, Foresman L, Adany I, Lifson J, McClure HM, Narayan O. 1998. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J Virol 72: 9069-9078.
32. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941. http://dx.doi.org/10.1126/science.1470917.
33. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. 1999. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73: 8356-8363.
34. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, Hall GA. 1997. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229: 143-154. http://dx.doi.org/10.1006/viro.1996.8419.
35. Girard MP, Osmanov S, Assossou OM, Kieny MP. 2011. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 29: 6191-6218. http://dx.doi.org/10.1016/j.vaccine .2011.06.085.
36. Hansen SG, Piatak M, Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Früh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ. 2013. Immune clearance of highly pathogenic SIV infection. Nature 502: 100-104. http://dx.doi.org/10.1038/nature12519.
37. George MD, Asmuth DM. 2014. Mucosal immunity in HIV infection: What can be done to restore gastrointestinal-Associated lymphoid tissue function? Curr Opin Infect Dis 27: 275-281. http://dx.doi.org/10.1097/QCO.0000000000000059.
38. Masopust D, Picker LJ. 2012. Hidden memories: Frontline memory T cells and early pathogen interception. J Immunol 188: 5811-5817. http://dx.doi.org/10.4049/jimmunol.1102695.
39. Tucker SN, Tingley DW, Scallan CD. 2008. Oral adenoviral-based vaccines: Historical perspective and future opportunity. Expert Rev Vaccines 7: 25-31. http://dx.doi.org/10.1586/14760584.7.1.25.
40. Kuschner RA, Russell KL, Abuja M, Bauer KM, Faix DJ, Hait H, Henrick J, Jacobs M, Liss A, Lynch JA, Liu Q, Lyons AG, Malik M, Moon JE, Stubbs J, Sun W, Tang D, Towle AC, Walsh DS, Wilkerson D, Adenovirus Vaccine Efficacy Trial Consortium. 2013. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine 31: 2963-2971.
41. Deal C, Pekosz A, Ketner G. 2013. Prospects for oral replicating adenovirus-vectored vaccines. Vaccine 31: 3236-3243. http://dx.doi.org/10 .1016/j.vaccine.2013.05.016.
42. Alexander J, Mendy J, Vang L, Avanzini JB, Garduno F, Manayani DJ, Ishioka G, Farness P, Ping LH, Swanstrom R, Parks R, Liao HX, Haynes BF, Montefiori DC, LaBranche C, Smith J, Gurwith M, Mayall T. 2013. Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. PLoS One 8: E82380. http://dx.doi.org/10.1371/journal.pone.0082380.